Dánsko -
dánština -
Lægemiddelstyrelsen (Danish Medicines Agency)
salmex 50+100 mikrog/dosis inhalationspulver, afdelt
2care4 aps - fluticasonpropionat, salmeterolxinafoat - inhalationspulver, afdelt - 50+100 mikrog/dosis
Dánsko -
dánština -
Lægemiddelstyrelsen (Danish Medicines Agency)
salmex 50+100 mikrog/dosis inhalationspulver, afdelt
orifarm a/s - fluticasonpropionat, salmeterolxinafoat - inhalationspulver, afdelt - 50+100 mikrog/dosis
Dánsko -
dánština -
Lægemiddelstyrelsen (Danish Medicines Agency)
salmex 50+100 mikrog/dosis inhalationspulver, afdelt
paranova danmark a/s - fluticasonpropionat, salmeterolxinafoat - inhalationspulver, afdelt - 50+100 mikrog/dosis
Dánsko -
dánština -
Lægemiddelstyrelsen (Danish Medicines Agency)
salmex 50+100 mikrog/dosis inhalationspulver, afdelt
orifarm a/s - fluticasonpropionat, salmeterolxinafoat - inhalationspulver, afdelt - 50+100 mikrog/dosis
Dánsko -
dánština -
Lægemiddelstyrelsen (Danish Medicines Agency)
seretide 50+100 mikrog./dosis inhalationspulver, afdelt
orifarm a/s - fluticasonpropionat, salmeterolxinafoat - inhalationspulver, afdelt - 50+100 mikrog./dosis
Dánsko -
dánština -
Lægemiddelstyrelsen (Danish Medicines Agency)
seretide 25+125 mikrog./dosis inhalationsspray, suspension
glaxosmithkline pharma a/s - fluticasonpropionat, salmeterolxinafoat - inhalationsspray, suspension - 25+125 mikrog./dosis
Dánsko -
dánština -
Lægemiddelstyrelsen (Danish Medicines Agency)
seretide 25+50 mikrogram inhalationsspray, suspension
glaxosmithkline pharma a/s - fluticasonpropionat, salmeterolxinafoat - inhalationsspray, suspension - 25+50 mikrogram
Evropská unie -
dánština -
EMA (European Medicines Agency)
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - medicin for obstruktiv sygdomme, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
Evropská unie -
dánština -
EMA (European Medicines Agency)
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - astma - medicin for obstruktiv sygdomme, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
Dánsko -
dánština -
Lægemiddelstyrelsen (Danish Medicines Agency)
mometasone sandoz 50 mikrogram/dosis næsespray, suspension
orifarm a/s - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis